

Integrating New Targets into Your Practice and Your Approach to Treatment

Clinical Brief Tweetorial #3

References

Tweet 8

ClinicalTrials.gov. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). NCT03694522. Updated May 3, 2021. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03694522>

ClinicalTrials.gov. A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). NCT03653507. Updated March 17, 2022. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03653507>

JEMPERLI (dostarlimab-gxly) [prescribing information]. GlaxoSmithKline. Approved 2021. Revised April 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf

KEYTRUDA® (pembrolizumab) [prescribing information]. Merck Sharp & Dohme Corp. Approved 2014. Revised March 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Esophageal and Esophagogastric Cancers (v2.2022). Updated February 11, 2022. Accessed March 30, 2022. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer (v2.2022). Updated January 11, 2021. Accessed March 30, 2022. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

OPDIVO (nivolumab) [prescribing information]. Bristol-Myers Squibb. Approved 2014. Revised March 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf

ROZLYTREK (entrectinib) [prescribing information]. Genentech. Approved 2019. Revised November 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212725s005lbl.pdf

VITRAKVI® (larotrectinib) [prescribing information]. Bayer HealthCare Pharmaceuticals Inc. Approved 2018. Revised March 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf

Tweet 12

Sahin U, Tureci O, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. *Ann Oncol*. 2021;32(5):609-619. doi:10.1016/j.annonc.2021.02.005

Tweet 13

Sahin U, Tureci O, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. *Ann Oncol*. 2021;32(5):609-619. doi:10.1016/j.annonc.2021.02.005

Tweet 14

ClinicalTrials.gov. A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). NCT03504397. Updated June 7, 2022. Accessed June 27, 2022. <https://clinicaltrials.gov/ct2/show/NCT03504397>

ClinicalTrials.gov. A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). NCT03653507. Updated March 17, 2022. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03653507>

Glossary

1L, first line
2L, second line
AE, adverse event
CAPOX, capecitabine/oxaliplatin
Chemo, chemotherapy
CLDN18.2, claudin-18 isoform 2
DCR, disease control rate
DOR, duration of response
EOX, epirubicin + oxaliplatin + capecitabine
FGFR2b, fibroblast growth factor receptor 2 isoform IIIb
FISH, fluorescence in situ hybridization
G, gastric
GEJ, gastroesophageal
HER2, human epidermal growth factor receptor 2
HRQOL, health-related quality of life
IHC, immunohistochemistry
ISH, in situ hybridization
LA, locally advanced
mDOR, median duration of response
MMR, mismatch repair
mOS, median overall survival
mPFS, median progression-free survival
MSI, microsatellite instability
NA, not applicable
NGS, next-generation sequencing
NTRK, neurotrophic tyrosine receptor kinase
ORR, objective response rate
OS, overall survival
PCR, polymerase chain reaction
PD-L1, programmed death-ligand 1
PFS, progression-free survival
Tx, treatment/therapy
w/, with